company background image
A078

MEDIPOST KOSDAQ:A078160 Stock Report

Last Price

₩21.35k

Market Cap

₩344.7b

7D

-3.2%

1Y

-33.3%

Updated

12 May, 2022

Data

Company Financials
A078160 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

A078160 Stock Overview

MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally.

MEDIPOST Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for MEDIPOST
Historical stock prices
Current Share Price₩21,350.00
52 Week High₩33,600.00
52 Week Low₩16,750.00
Beta0.88
1 Month Change-15.95%
3 Month Change19.27%
1 Year Change-33.28%
3 Year Change-35.89%
5 Year Change-34.61%
Change since IPO3.14%

Recent News & Updates

Mar 11
Is MEDIPOST (KOSDAQ:078160) Weighed On By Its Debt Load?

Is MEDIPOST (KOSDAQ:078160) Weighed On By Its Debt Load?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Jan 17
MEDIPOST's (KOSDAQ:078160) Stock Price Has Reduced 32% In The Past Three Years

MEDIPOST's (KOSDAQ:078160) Stock Price Has Reduced 32% In The Past Three Years

MEDIPOST Co., Ltd. ( KOSDAQ:078160 ) shareholders should be happy to see the share price up 29% in the last quarter...

Nov 24
Is MEDIPOST (KOSDAQ:078160) A Risky Investment?

Is MEDIPOST (KOSDAQ:078160) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

A078160KR HealthcareKR Market
7D-3.2%-0.8%-3.3%
1Y-33.3%-38.5%-14.3%

Return vs Industry: A078160 exceeded the KR Healthcare industry which returned -38.5% over the past year.

Return vs Market: A078160 underperformed the KR Market which returned -14.3% over the past year.

Price Volatility

Is A078160's price volatile compared to industry and market?
A078160 volatility
A078160 Average Weekly Movement7.6%
Healthcare Industry Average Movement5.7%
Market Average Movement5.5%
10% most volatile stocks in KR Market10.4%
10% least volatile stocks in KR Market3.1%

Stable Share Price: A078160 is more volatile than 75% of KR stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: A078160's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2000267Yoon Yanghttps://www.medi-post.co.kr

MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis.

MEDIPOST Fundamentals Summary

How do MEDIPOST's earnings and revenue compare to its market cap?
A078160 fundamental statistics
Market Cap₩344.70b
Earnings (TTM)-₩683.26m
Revenue (TTM)₩54.86b

6.3x

P/S Ratio

-504.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A078160 income statement (TTM)
Revenue₩54.86b
Cost of Revenue₩22.99b
Gross Profit₩31.86b
Other Expenses₩32.55b
Earnings-₩683.26m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-42.32
Gross Margin58.08%
Net Profit Margin-1.24%
Debt/Equity Ratio17.4%

How did A078160 perform over the long term?

See historical performance and comparison

Valuation

Is MEDIPOST undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


2.16x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A078160's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A078160's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: A078160 is unprofitable, so we can't compare its PE Ratio to the Asian Healthcare industry average.

PE vs Market: A078160 is unprofitable, so we can't compare its PE Ratio to the KR market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A078160's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: A078160's PB Ratio (2.2x) is in line with the KR Healthcare industry average.


Future Growth

How is MEDIPOST forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


17.0%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MEDIPOST has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has MEDIPOST performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-3.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A078160 is currently unprofitable.

Growing Profit Margin: A078160 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: A078160 is unprofitable, and losses have increased over the past 5 years at a rate of 3.8% per year.

Accelerating Growth: Unable to compare A078160's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A078160 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (33.4%).


Return on Equity

High ROE: A078160 has a negative Return on Equity (-0.6%), as it is currently unprofitable.


Financial Health

How is MEDIPOST's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A078160's short term assets (₩81.1B) exceed its short term liabilities (₩41.4B).

Long Term Liabilities: A078160's short term assets (₩81.1B) exceed its long term liabilities (₩50.5B).


Debt to Equity History and Analysis

Debt Level: A078160 has more cash than its total debt.

Reducing Debt: A078160's debt to equity ratio has increased from 15.4% to 17.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A078160 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: A078160 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 29.4% each year


Dividend

What is MEDIPOST current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A078160's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A078160's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A078160's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A078160's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A078160 has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Yoon Yang (57 yo)

no data

Tenure

Dr. Yoon Sun Yang serves as Chief Executive Officer and President of Medipost Co. Ltd. Dr. Yang served as Chief Director of Medipost and President of Medipost Co. Ltd. He is a Professor in Samsung Medical...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MEDIPOST Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: MEDIPOST Co., Ltd.
  • Ticker: A078160
  • Exchange: KOSDAQ
  • Founded: 2000
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: ₩344.700b
  • Shares outstanding: 16.15m
  • Website: https://www.medi-post.co.kr

Number of Employees


Location

  • MEDIPOST Co., Ltd.
  • 21, Daewangpangyo-ro
  • 644 beon-gil
  • Seongnam-si
  • Gyeonggi-do
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/12 00:00
End of Day Share Price2022/05/12 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.